FDA granted breakthrough therapy designation for Lenvatinib in combination with Pembrolizumab for patients with advanced and/or metastatic renal cell carcinoma
Multiple receptor tyrosine kinase inhibitor Lenvatinib ( Lenvima ) and anti–PD-1 therapy Pembrolizumab ( Keytruda ) as a combination therapy for patients with renal cell carcinoma received the designa ...
read article